Compare iShares MBS ETF (MBB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MBS ETF trades at $89.99 (market cap $35.58B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: iShares MBS ETF is far larger — about 36.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 97 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MBB | MRVI | |
|---|---|---|
Market Cap | $35.58B | $972.90M |
Volume | 3,918,815 | 4,325,710 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $9.00 |
52-Week Low | $89.09 | $2.83 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB trades at $90.00 with minimal daily movement (+0.19%). Technical indicators signal bearish momentum with RSI at overbought levels and moving averages trending downward. Recent news highlights significant short interest growth (98.3% increase in September 2026) and concerns about intermediate duration risk amid potential rate hikes. The ETF faces pressure from rising rates while maintaining consistent dividend distributions.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. While institutional buying provides some support, the combination of high short interest and duration risk creates headwinds. Investors should weigh the steady income against potential price depreciation in a rising rate environment.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
